心肺バイパス装置の世界市場：洞察、競合情勢、市場予測：2030年

心肺バイパス装置の市場規模は、2023年に4億518万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に4.14％のCAGRで拡大し、2030年には5億1,682万米ドルに達すると予測されています。心肺バイパス装置の需要は、世界的に心血管疾患や呼吸器疾患の有病率が上昇し、外科的介入の必要性が高まっていることが背景にあります。冠動脈疾患、心不全、先天性心疾患などの疾患では複雑な手術が必要とされることが多く、心肺バイパス装置によって手術が容易になります。第二に、人口の高齢化と医療技術の進歩によって外科手術の件数が増加していることが、心肺バイパス装置の需要を高めています。手術件数が増えれば、信頼性が高く効率的な心肺バイパス装置のニーズも高まります。第三に、心血管系および呼吸器系疾患の早期発見・診断に寄与しているのが、認知度の向上とスクリーニングプログラムです。早期発見はタイムリーな外科的介入につながることが多く、心肺バイパス装置の需要をさらに押し上げています。さらに、世界中の主要市場参入企業による製品の発売と承認の増加により、先進的な人工心肺装置の入手可能性とアクセシビリティが拡大しています。技術革新と設計の改善により、より効率的で安全、使いやすい機器が生み出され、2024年から2030年までの予測期間中、医療従事者の間で採用率が高まっています。

英国心臓財団（British Heart Foundation）の最新データ（2024年）によると、世界全体で約6億2,000万人、約13人に1人が心臓・循環器疾患を抱えています。また、同資料によると、2021年の心臓・循環器疾患の有病率は欧州で1億人、アジア・オーストラリアで3億4,000万人でした。さらに、英国心臓財団が提供した最近のデータ（2024年）によると、世界で最も多く診断されている冠動脈（虚血性）心疾患は、世界で推定2億人が罹患しています。約1億1,000万人の男性と8,000万人の女性が罹患しています。さらに、約5,600万人の女性と4,500万人の男性が脳卒中の生存者です。世界中で少なくとも1,300万人が先天性心疾患を患っていると推定され、さらに数百万人が診断されていない可能性があります。

冠動脈（虚血性）心疾患、心房細動、脳卒中などの心臓および循環器疾患は、その有病率およびしばしば外科的介入を必要とする治療の複雑さにより、集合的に心肺バイパス装置の需要を牽引しています。これらの手術は、循環機能と呼吸機能を維持するために心肺バイパス装置に大きく依存しています。プラークが蓄積して血流が低下する冠動脈性心疾患では、冠動脈バイパス移植術（CABG）が頻繁に必要となり、人工心肺装置の需要を大幅に押し上げています。最も一般的な不整脈である心房細動は、脳卒中や心不全のリスクを高め、メイズ手術やカテーテルアブレーションなどの手術につながりますが、これらも心肺バイパスのサポートに依存しています。同様に、血流の閉塞によって引き起こされる脳卒中は、循環を回復させるために心肺バイパス装置に依存する外科的介入を必要とすることが多く、世界の市場の成長をさらに促進しています。

当レポートでは、世界の心肺バイパス装置市場について調査し、市場の概要とともに、製品別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 心肺バイパス装置市場レポートのイントロダクション

第2章 心肺バイパス装置市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 心肺バイパス装置市場の主な要因分析

• 心肺バイパス装置の市場促進要因
• 心肺バイパス装置の市場抑制要因と課題
• 心肺バイパス装置の市場機会

第6章 心肺バイパス装置市場におけるポーターのファイブフォース分析

第7章 心肺バイパス装置市場の評価

• 製品別
  • 人工心肺装置
  • 酸素供給装置
  • 自己輸血システム
  • その他
• 用途別
  • 心臓血管
  • 呼吸器
  • 血液透析
• エンドユーザー別
  • 病院
  • 専門クリニック
  • 透析センター
  • 外来手術センター
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 心肺バイパス装置市場の企業と製品プロファイル

• Medtronic plc.
• LivaNova PLC
• MAQUET Holding B.V. & Co. KG.
• ABIOMED
• Braile Biomedica Ltd.
• Tianjin Medical
• Terumo Corp.
• Senko Medical Instrument Manufacturing Co.,Ltd.
• Technowood Corp
• Sorin
• MicroPort Scientific Corporation
• Xenios AG
• Nipro Corporation
• OriGen Biomedical
• Thoratec Corporation
• Inspira Technologies OXY B.H.N. Ltd.
• Xenios AG
• Boston Scientific Corporation
• Cardinal Health
• B. Braun

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Cardiopulmonary Bypass Equipment Market in Global (2021-2030)
• Table 3: Cardiopulmonary Bypass Equipment Market in Global by Product (2021-2030)
• Table 4: Cardiopulmonary Bypass Equipment Market in Global by Application (2021-2030)
• Table 5: Cardiopulmonary Bypass Equipment Market in Global by End-User (2021-2030)
• Table 6: Cardiopulmonary Bypass Equipment Market in Global by Geography (2021-2030)
• Table 7: Cardiopulmonary Bypass Equipment Market in North America (2021-2030)
• Table 8: Cardiopulmonary Bypass Equipment Market in the United States (2021-2030)
• Table 9: Cardiopulmonary Bypass Equipment Market in Canada (2021-2030)
• Table 10: Cardiopulmonary Bypass Equipment Market in Mexico (2021-2030)
• Table 11: Cardiopulmonary Bypass Equipment Market in Europe (2021-2030)
• Table 12: Cardiopulmonary Bypass Equipment Market in France (2021-2030)
• Table 13: Cardiopulmonary Bypass Equipment Market in Germany (2021-2030)
• Table 14: Cardiopulmonary Bypass Equipment Market in United Kingdom (2021-2030)
• Table 15: Cardiopulmonary Bypass Equipment Market in Italy (2021-2030)
• Table 16: Cardiopulmonary Bypass Equipment Market in Spain (2021-2030)
• Table 17: Cardiopulmonary Bypass Equipment Market in the Rest of Europe (2021-2030)
• Table 18: Cardiopulmonary Bypass Equipment Market in Asia-Pacific (2021-2030)
• Table 19: Cardiopulmonary Bypass Equipment Market in China (2021-2030)
• Table 20: Cardiopulmonary Bypass Equipment Market in Japan (2021-2030)
• Table 21: Cardiopulmonary Bypass Equipment Market in India (2021-2030)
• Table 22: Cardiopulmonary Bypass Equipment Market in Australia (2021-2030)
• Table 23: Cardiopulmonary Bypass Equipment Market in South Korea (2021-2030)
• Table 24: Cardiopulmonary Bypass Equipment Market in Rest of Asia-Pacific (2021-2030)
• Table 25: Cardiopulmonary Bypass Equipment Market in the Rest of the World (2021-2030)
• Table 26: Cardiopulmonary Bypass Equipment Market in the Middle East (2021-2030)
• Table 27: Cardiopulmonary Bypass Equipment Market in Africa (2021-2030)
• Table 28: Cardiopulmonary Bypass Equipment Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Cardiopulmonary Bypass Equipment Market in Global (2021-2030)
• Figure 3: Cardiopulmonary Bypass Equipment Market in Global by Product (2021-2030)
• Figure 4: Cardiopulmonary Bypass Equipment Market in Global by Application (2021-2030)
• Figure 5: Cardiopulmonary Bypass Equipment Market in Global by End-User (2021-2030)
• Figure 6: Cardiopulmonary Bypass Equipment Market in Global by Geography (2021-2030)
• Figure 7: Cardiopulmonary Bypass Equipment Market in North America (2021-2030)
• Figure 8: Cardiopulmonary Bypass Equipment Market in the United States (2021-2030)
• Figure 9: Cardiopulmonary Bypass Equipment Market in Canada (2021-2030)
• Figure 10: Cardiopulmonary Bypass Equipment Market in Mexico (2021-2030)
• Figure 11: Cardiopulmonary Bypass Equipment Market in Europe (2021-2030)
• Figure 12: Cardiopulmonary Bypass Equipment Market in France (2021-2030)
• Figure 13: Cardiopulmonary Bypass Equipment Market in Germany (2021-2030)
• Figure 14: Cardiopulmonary Bypass Equipment Market in United Kingdom (2021-2030)
• Figure 15: Cardiopulmonary Bypass Equipment Market in Italy (2021-2030)
• Figure 16: Cardiopulmonary Bypass Equipment Market in Spain (2021-2030)
• Figure 17: Cardiopulmonary Bypass Equipment Market in the Rest of Europe (2021-2030)
• Figure 18: Cardiopulmonary Bypass Equipment Market in Asia-Pacific (2021-2030)
• Figure 19: Cardiopulmonary Bypass Equipment Market in China (2021-2030)
• Figure 20: Cardiopulmonary Bypass Equipment Market in Japan (2021-2030)
• Figure 21: Cardiopulmonary Bypass Equipment Market in India (2021-2030)
• Figure 22: Cardiopulmonary Bypass Equipment Market in Australia (2021-2030)
• Figure 23: Cardiopulmonary Bypass Equipment Market in South Korea (2021-2030)
• Figure 24: Cardiopulmonary Bypass Equipment Market in Rest of Asia-Pacific (2021-2030)
• Figure 25: Cardiopulmonary Bypass Equipment Market in the Rest of the World (2021-2030)
• Figure 26: Cardiopulmonary Bypass Equipment Market in the Middle East (2021-2030)
• Figure 27: Cardiopulmonary Bypass Equipment Market in Africa (2021-2030)
• Figure 28: Cardiopulmonary Bypass Equipment Market in South America (2021-2030)
• Figure 29: Market Drivers
• Figure 30: Market Barriers
• Figure 31: Market Opportunities
• Figure 32: PORTER'S Five Force Analysis

Cardiopulmonary Bypass Equipment Market by Product (Heart-Lung Machines, Oxygenators, Autotransfusion Systems, and Others), Application (Cardiovascular, Respiratory, Hemodialysis, and Others), End-User (Hospitals, Specialty Clinics, Dialysis Centers, and Ambulatory Surgery Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising burden of cardiovascular diseases and respiratory diseases, increasing number of surgical procedures, increasing awareness and screening programs, and increase in product launches and approvals by key market players across the globe.

The cardiopulmonary bypass equipment market was valued at USD 405.18 million in 2023, growing at a CAGR of 4.14% during the forecast period from 2024 to 2030, to reach USD 516.82 million by 2030. The demand for cardiopulmonary bypass equipment is motivated by a rise in the prevalence of cardiovascular and respiratory diseases globally which has led to an increased need for surgical interventions. Conditions such as coronary artery disease, heart failure, and congenital heart defects often require complex surgeries, which are facilitated by cardiopulmonary bypass equipment. Secondly, the increasing number of surgical procedures, driven by an aging population and advancements in medical technology, has heightened the demand for cardiopulmonary bypass equipment. More surgeries translate to a greater need for reliable and efficient cardiopulmonary bypass equipment. Thirdly, growing awareness and screening programs are contributing to the early detection and diagnosis of cardiovascular and respiratory conditions. Early detection often leads to timely surgical interventions, further driving the demand for cardiopulmonary bypass equipment. Furthermore, the increase in product launches and approvals by key market players across the globe has expanded the availability and accessibility of advanced cardiopulmonary bypass equipment. Innovations in technology and design improvements are resulting in more efficient, safer, and user-friendly equipment, which enhances the adoption rates among healthcare providers during the forecast period from 2024 to 2030.

Cardiopulmonary Bypass Equipment Market Dynamics:

According to recent data provided by the British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, live with heart and circulatory diseases. Additionally, as per the same source, the prevalence of heart and circulatory diseases was 100 million in Europe and 340 million in Asia and Australia in 2021. Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, the most commonly diagnosed worldwide, affects an estimated 200 million people globally. Approximately 110 million men and 80 million women are affected. Additionally, around 56 million women and 45 million men are stroke survivors. It is estimated that at least 13 million people worldwide live with congenital heart disease, with potentially millions more undiagnosed.

According to the World Heart Federation (2024), approximately 60 million population are affected by atrial fibrillation which is one of the most common types of irregular heartbeat, or arrhythmia. It can increase the risk of blood clots, heart failure, and stroke. Additionally, as per the same source people with atrial fibrillation are 5X times more likely to suffer a stroke.

Furthermore, according to the recent data and stats provided by the Australian Institute of Health and Welfare (2024), in 2021, more than 500,000 population were affected by atrial fibrillation.

Heart and circulatory diseases, including coronary (ischemic) heart disease, atrial fibrillation, and stroke, collectively drive the demand for cardiopulmonary bypass equipment due to their prevalence and the complexity of treatments often requiring surgical intervention. These surgeries depend heavily on cardiopulmonary bypass equipment to maintain circulatory and respiratory functions. Coronary heart disease, resulting from plaque buildup and reduced blood flow, frequently necessitates coronary artery bypass grafting (CABG), significantly boosting cardiopulmonary bypass equipment demand. Atrial fibrillation, the most common arrhythmia, increases stroke and heart failure risks, leading to surgeries like the maze procedure or catheter ablation, which also rely on cardiopulmonary bypass support. Similarly, strokes caused by blood flow blockages often require surgical interventions that depend on cardiopulmonary bypass equipment to restore circulation, further driving market growth globally.

Additionally, companies are amplifying their production of cardiopulmonary bypass equipment and securing regulatory approvals, thereby strategically expanding their market presence and driving further growth. For instance, in July 2024, Inspira(TM) Technologies OXY B.H.N. Ltd. received the Israeli Ministry of Health's medical devices and accessories ("AMAR") approval for the INSPIRA(TM) ART100, an extra-corporeal membrane oxygenation and cardiopulmonary bypass system.

Thus, the factors mentioned above are likely to boost the market for cardiopulmonary bypass equipment during the forecasted period.

However, cardiopulmonary bypass equipment can lead to various complications, including bleeding, infection, neurological deficits, renal dysfunction, and respiratory issues, and stringent regulatory concerns for product approval may hinder the future market of cardiopulmonary bypass equipment.

Cardiopulmonary Bypass Equipment Market Segment Analysis:

Cardiopulmonary Bypass Equipment Market by Product (Heart-Lung Machines, Oxygenators, Autotransfusion Systems, and Others), Application (Cardiovascular, Respiratory, Hemodialysis, and Others), End-User (Hospitals, Specialty Clinics, Dialysis Centers, and Ambulatory Surgery Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the cardiopulmonary bypass equipment market, heart-lung machines are projected to hold a considerable market share in 2023. Heart-lung machines, a critical component of cardiopulmonary bypass (CPB) systems, play a pivotal role in boosting the overall market for CPB equipment by enhancing the scope and efficacy of cardiac and thoracic surgeries. These machines temporarily assume the functions of the heart and lungs, allowing for complex surgical procedures on a still and bloodless heart, which is essential for precision in surgeries such as coronary artery bypass grafting (CABG), heart valve replacements, and heart transplants. The growing prevalence of cardiovascular diseases and respiratory diseases has driven an increasing number of surgical interventions that rely on heart-lung machines. For instance, according to the latest data provided by the Australian Institute of Health and Welfare, in 2022, around 8.5 million (34%) people in Australia were estimated to have chronic respiratory conditions. Thus, as the cases of respiratory disorders and cardiovascular diseases increase so does the demand for such high-risk and intricate procedures, which also increases the need for advanced heart-lung machines, fueling the market growth. Innovations in heart-lung machine technology such as improved oxygenators, more efficient pumps, and enhanced biocompatibility have led to better patient outcomes, fewer complications, and increased acceptance among healthcare providers.

Additionally, the regulatory approvals and advancements in technology have further bolstered market growth by providing more reliable and sophisticated equipment options, thus encouraging widespread adoption. For instance, in April 2022, LivaNova received FDA 510(k) clearance for its B-Capta system integrated into the S5 heart-lung machine.

Therefore, owing to the above-mentioned factors, the heart-lung machines category is expected to generate considerable revenue thereby pushing the overall growth of the cardiopulmonary bypass equipment market during the forecast period.

North America is expected to dominate the overall cardiopulmonary bypass equipment market:

North America is expected to account for the highest proportion of the cardiopulmonary bypass equipment market in 2023, out of all regions. This can be ascribed to the increasing prevalence of cardiac disease and respiratory disease across the region, increased government initiatives coupled with increased awareness programs for cardiac and respiratory disease, and the presence of key market players engaged in mergers, acquisitions, product launches, and other market activities across the region are expected to escalate the market of cardiopulmonary bypass equipment during the forecast period.

According to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.

Moreover, as per the recent data provided by the Centre for Disease Control and Prevention (2024), approximately 900,000 people in the United States are affected by venous thromboembolism (VTE, a blood clot), each year. Furthermore, as per the same source, in 2022, approximately 4.6% of U.S. adults have been diagnosed with COPD, emphysema, or chronic bronchitis.

Coronary heart disease frequently leads to severe cases requiring coronary artery bypass grafting, which relies heavily on cardiopulmonary bypass equipment to maintain heart and lung function during surgery. Atrial fibrillation, with its increased risk of stroke and heart failure, often necessitates surgical procedures that depend on cardiopulmonary bypass equipment systems for stable circulation and oxygenation. Stroke, particularly in its severe forms, may require surgical interventions to restore proper blood flow, again driving the need for cardiopulmonary bypass equipment. Furthermore, venous thromboembolism, involving conditions like deep vein thrombosis and pulmonary embolism, sometimes necessitates surgical removal of clots, a procedure that also benefits from cardiopulmonary bypass equipment support. COPD patients undergoing lung volume reduction surgery or lung transplantation require cardiopulmonary bypass equipment systems to manage their circulatory and respiratory functions during complex procedures. The high incidence of these conditions is escalating the market of cardiopulmonary bypass equipment across the region.

Additionally, the awareness programs in the United States aimed at addressing cardiac diseases focus on education, prevention, and early detection also boost the market of Cardiopulmonary Bypass Equipment across the region as public awareness campaigns educate individuals about the importance of regular screenings and preventive measures. For example, February is designated as American Heart Month, during which various organizations, including the American Heart Association (AHA) and the Centers for Disease Control and Prevention (CDC), promote awareness through campaigns, events, and educational materials. These efforts emphasize the importance of heart health, risk factors, and preventive measures.

The increasing number of product development activities in the region is further going to accelerate the growth of the cardiopulmonary bypass equipment market. For example, in March 2023 the US Food and Drug Administration (FDA) granted 510(k) clearance to LivaNova's Essenz heart-lung machine (HLM) for use in cardiopulmonary bypass (CPB) procedures.

Therefore, the above-mentioned factors are expected to bolster the growth of the cardiopulmonary bypass equipment market in North America during the forecast period.

Cardiopulmonary Bypass Equipment Market Key Players:

Some of the key market players operating in the cardiopulmonary bypass equipment market include Medtronic plc., LivaNova PLC, MAQUET Holding B.V. & Co. KG., ABIOMED, Braile Biomedica Ltda, Tianjin Medical, Terumo Corp, Senko Medical Instrument Manufacturing Co., Ltd., Technowood Corp, Sorin, MicroPort Scientific Corporation, Xenios AG, Nipro Corporation, OriGen Biomedical, Thoratec Corporation, Inspira Technologies OXY B.H.N. Ltd., Xenios AG, Boston Scientific, Cardinal Health, B. Braun, and others.

Recent Developmental Activities in the Cardiopulmonary Bypass Equipment Market:

• In May 2024, Terumo Corporation, a global leader in cardiovascular surgery technologies, announced that the U.S. Food and Drug Administration (FDA) had granted 510(k) clearance for the CDI OneView Monitoring System. This next-generation CDI Systems platform provided enhanced visibility of key patient parameters during cardiopulmonary bypass surgery
• In August 2022, the FDA awarded breakthrough privileges to Abiomed's Impella ECP expandable percutaneous heart pump.

Key Takeaways From the Cardiopulmonary Bypass Equipment Market Report Study:

• Market size analysis for current cardiopulmonary bypass equipment size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the cardiopulmonary bypass equipment market.
• Various opportunities available for the other competitors in the cardiopulmonary bypass equipment market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current cardiopulmonary bypass equipment market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for cardiopulmonary bypass equipment market growth in the coming future?

Target Audience who can be Benefited From This Cardiopulmonary Bypass Equipment Market Report Study:

• Cardiopulmonary bypass equipment product providers
• Research organizations and consulting companies
• Cardiopulmonary bypass equipment -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in cardiopulmonary bypass equipment
• Various end-users want to know more about the cardiopulmonary bypass equipment market and the latest technological developments in the cardiopulmonary bypass equipment market.

Frequently Asked Questions for the Cardiopulmonary Bypass Equipment Market:

1. What are cardiopulmonary bypass equipment?

Cardiopulmonary bypass (CPB) equipment provides a bloodless field for cardiac surgery and does the work of both the heart (i.e., pumps blood) and the lungs (i.e., oxygenates the blood). CPB circuit includes pumps, cannulae, tubing, reservoir, oxygenator, heat exchanger, and arterial line filter. Cardiopulmonary bypass machines are operated by perfusionists to bypass the heart and lungs during open-heart surgery.

2. What is the market for cardiopulmonary bypass equipment?

The cardiopulmonary bypass equipment market was valued at USD 405.18 million in 2023, growing at a CAGR of 4.14% during the forecast period from 2024 to 2030, to reach USD 516.82 million by 2030.

3. What are the drivers for the cardiopulmonary bypass equipment market?

The demand for cardiopulmonary bypass equipment is motivated by a rise in the prevalence of cardiovascular and respiratory diseases globally which has led to an increased need for surgical interventions. Conditions such as coronary artery disease, heart failure, and congenital heart defects often require complex surgeries, which are facilitated by cardiopulmonary bypass equipment. Secondly, the increasing number of surgical procedures, driven by an aging population and advancements in medical technology, has heightened the demand for cardiopulmonary bypass equipment. More surgeries translate to a greater need for reliable and efficient cardiopulmonary bypass equipment. Thirdly, growing awareness and screening programs are contributing to the early detection and diagnosis of cardiovascular and respiratory conditions. Early detection often leads to timely surgical interventions, further driving the demand for cardiopulmonary bypass equipment. Furthermore, the increase in product launches and approvals by key market players across the globe has expanded the availability and accessibility of advanced cardiopulmonary bypass equipment. Innovations in technology and design improvements are resulting in more efficient, safer, and user-friendly equipment, which enhances the adoption rates among healthcare providers during the forecast period from 2024 to 2030.

4. Who are the key players operating in the cardiopulmonary bypass equipment market?

Some of the key market players operating in the Cardiopulmonary Bypass Equipment market include Medtronic plc., LivaNova PLC, MAQUET Holding B.V. & Co. KG., ABIOMED, Braile Biomedica Ltda, Tianjin Medical, Terumo Corp, Senko Medical Instrument Manufacturing Co., Ltd., Technowood Corp, Sorin, MicroPort Scientific Corporation, Xenios AG, Nipro Corporation, OriGen Biomedical, Thoratec Corporation, Inspira Technologies OXY B.H.N. Ltd., Xenios AG, Boston Scientific, Cardinal Health, B. Braun, and others.

5. Which region has the highest share in the cardiopulmonary bypass equipment market?

North America is expected to account for the highest proportion of the cardiopulmonary bypass equipment market in 2023, out of all regions. This can be ascribed to the increasing prevalence of cardiac disease and respiratory disease across the region, increased government initiatives coupled with increased awareness programs for cardiac and respiratory disease, and the presence of key market players engaged in merges, acquisition, product launches, and other market activities across the region are expected to escalate the market of cardiopulmonary bypass equipment during the forecast period.

Table of Contents

1. Cardiopulmonary Bypass Equipment Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Cardiopulmonary Bypass Equipment Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Cardiopulmonary Bypass Equipment Market Key Factors Analysis

• 5.1. Cardiopulmonary Bypass Equipment Market Drivers
  • 5.1.1. The rising burden of cardiac diseases and respiratory disease
  • 5.1.2. Increasing number of surgical procedures
  • 5.1.3. Increasing awareness and screening programs
  • 5.1.4. Increase in product launches and approvals by key market players across the globe
• 5.2. Cardiopulmonary Bypass Equipment Market Restraints and Challenges
  • 5.2.1. Cardiopulmonary bypass equipment carries risks such as bleeding, infection, neurological deficits, renal dysfunction, and respiratory issues
  • 5.2.2. Stringent regulatory concerns for product approval
• 5.3. Cardiopulmonary Bypass Equipment Market Opportunities
  • 5.3.1. Integration of cardiopulmonary bypass equipment with emerging technologies like artificial intelligence (AI) and machine learning

6. Cardiopulmonary Bypass Equipment Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Cardiopulmonary Bypass Equipment Market Assessment

• 7.1. By Product
  • 7.1.1. Heart-Lung Machines
  • 7.1.2. Oxygenators
  • 7.1.3. Autotransfusion Systems
  • 7.1.4. Others
• 7.2. By Application
  • 7.2.1. Cardiovascular
  • 7.2.2. Respiratory
  • 7.2.3. Hemodialysis
  • 7.2.4. Others
• 7.3. By End-User
  • 7.3.1. Hospitals
  • 7.3.2. Specialty Clinics
  • 7.3.3. Dialysis Centers
  • 7.3.4. Ambulatory Surgical Centers
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.1.2. Canada Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.1.3. Mexico Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.2.2. Germany Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.2.3. United Kingdom Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.2.4. Italy Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.2.5. Spain Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.2.6. Rest of Europe Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.3.2. Japan Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.3.3. India Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.3.4. Australia Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.3.5. South Korea Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.3.6. Rest of Asia-Pacific Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.4.2. Africa Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)
    • 7.4.4.3. South America Cardiopulmonary Bypass Equipment Market Size in USD Million (2021-2030)

8. Cardiopulmonary Bypass Equipment Market Company and Product Profiles

• 8.1. Medtronic plc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. LivaNova PLC
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. MAQUET Holding B.V. & Co. KG.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. ABIOMED
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Braile Biomedica Ltd.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Tianjin Medical
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Terumo Corp.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Senko Medical Instrument Manufacturing Co.,Ltd.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Technowood Corp
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Sorin
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. MicroPort Scientific Corporation
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Xenios AG
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Nipro Corporation
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. OriGen Biomedical
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Thoratec Corporation
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Inspira Technologies OXY B.H.N. Ltd.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Xenios AG
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Boston Scientific Corporation
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Cardinal Health
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. B. Braun
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us